$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How effective is Mobotinib as a targeted therapy for lung cancer?
2026-02-01 22:25:32
Check Details
How to choose between Suvotinib and Mobotinib (Mobosetinib)
2026-02-01 22:25:32
Check Details
What are the dietary precautions while taking lorlatinib (lorlatinib)?
2026-02-01 22:25:32
Check Details
Lorlatinib's remarkable effectiveness in the treatment of non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Contraindications and precautions when using lorlatinib
2026-02-01 22:25:32
Check Details
Lorlatinib (lorlatinib) resistance problem analysis and countermeasures
2026-02-01 22:25:32
Check Details
Turkish version of lorlatinib (lorlatinib) price advantage and drug purchasing guide
2026-02-01 22:25:32
Check Details
Ten key considerations when treating regorafenib
2026-02-01 22:25:32
Check Details
Analysis of the therapeutic effect of regorafenib on colorectal cancer
2026-02-01 22:25:32
Check Details
Analysis of the application and effect of regorafenib in the treatment of gastrointestinal stromal tumors
2026-02-01 22:25:32
Check Details
How long does it take to see the effects of regorafenib treatment?
2026-02-01 22:25:32
Check Details
What does ponatinib do?
2026-02-01 22:25:32
Check Details
1
2
...
791
792
793
794
795
796
797
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
4
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Revumenib: Key Considerations Before and During Treatment
7
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
8
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
9
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
10
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
11
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
12
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits